查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070499

失眠治療市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026-2034年預測。

Insomnia Drugs Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

失眠治療市場的成長要素

全球失眠治療市場預計到2025年將達到45億美元，並從2026年的48.6億美元成長到2034年的89億美元，預測期內複合年成長率（CAGR）為7.86%。北美將引領市場，到2025年將佔44.88%的市場佔有率，這主要得益於該地區睡眠障礙的高發生率、完善的醫療保健基礎設施以及創新型失眠療法的快速普及。

失眠已成為全球最常見的睡眠障礙之一，影響著數百萬各年齡層的人。壓力水平上升、焦慮、憂鬱症、生活方式改變、過度使用電子螢幕以及不規律的工作時間，導致尋求睡眠相關疾病治療的人數顯著增加。為了應對日益嚴重的慢性失眠問題，製藥公司正在研發更安全、更有效的治療方法，以改善夜間睡眠品質和日間功能。

市場正經歷著向新一代療法的顯著轉變，尤其是雙重Orexin受體拮抗劑（DORA），與傳統催眠藥相比，這類藥物療效較佳，且能減少日間嗜睡。預計主要製藥公司持續的研發活動將推動未來市場成長。

市場趨勢

對更安全、更容易耐受的失眠治療方法的需求日益成長

失眠治療市場最顯著的趨勢之一是，人們對能夠有效改善睡眠且副作用更少的療法的需求日益成長。由於擔心成癮、認知障礙和持續性日間嗜睡等問題，患者和醫療保健專業人員對傳統安眠藥越來越謹慎。

因此，諸如Orexin受體拮抗劑等新型療法正日益普及。這些藥物旨在促進自然睡眠模式，同時最大限度地減少晨起功能障礙。人們越來越重視改善睡眠品質和日間表現，這正在改變全球的處方模式。

市場促進因素

失眠和睡眠障礙的盛行率增加

市場成長的主要促進因素是全球失眠盛行率的快速上升。人們對心理健康的日益關注、人口老化、工作壓力以及慢性疾病等因素，都導致睡眠障礙患者人數顯著增加。

近期全球調查顯示，全球有超過8.5億成年人患有失眠症，導致藥物治療的需求顯著增加。隨著人們對睡眠健康重要性的認知不斷提高，失眠症的診斷率和治療需求預計將進一步成長，從而推動市場長期擴張。

市場限制因素

長期用藥相關的安全問題

儘管需求不斷成長，但長期安全性問題仍是市場面臨的一大挑戰。有些失眠藥物與藥物依賴性、跌倒、殘留鎮靜作用和認知障礙等風險增加有關，尤其是在老年患者中。

醫療保健專業人員通常建議短期使用某些睡眠藥物，這限制了處方量的長期成長。這些顧慮持續影響處方決策，並減緩了某些藥物類別的普及。

市場機遇

人們對睡眠健康的認知不斷提高

人們對睡眠對身心健康影響的認知不斷提高，為市場拓展帶來了巨大的機會。患者越來越積極主動地尋求治療慢性睡眠障礙，而醫療保健專業人員也正將睡眠管理納入綜合健康計畫的優先事項中。

製藥公司也透過合作、授權協議和商業化努力，擴大其在新興市場的業務，以改善人們獲得創新失眠療法的機會。

市場挑戰

與學名藥的競爭和專利到期

失眠治療市場面臨的主要挑戰之一是學名藥的日益普及。隨著專利到期，價格更低的學名藥正在不斷擴大市場佔有率，從而減少了品牌藥生產商的商機。

學名藥的價格壓力加劇了競爭，迫使製藥公司專注於創新和產品差異化，以維持盈利。

區域分析

北美洲

預計北美將引領全球市場，到 2025 年市場規模將達到 20.2 億美元。人們對睡眠障礙的認知不斷提高、有利的保險報銷政策以及創新失眠療法的迅速普及，將繼續推動市場成長。

預計到 2026 年，美國失眠治療市場規模將達到 20.1 億美元，約佔全球整體銷售額的 41.29%。

歐洲

預計2026年，歐洲市場規模將達到13.1億美元，複合年成長率為7.79%。醫生對DORA療法的信心不斷增強以及保險報銷支持的擴大正在推動市場擴張。

德國和英國仍然是最大的區域市場之一。

亞太地區

預計到 2026 年，亞太地區的市場規模將達到 10.1 億美元，這主要得益於人們對睡眠健康的日益關注、醫療保健支出的增加以及品牌失眠藥物的廣泛應用。

預計到 2026 年，中國銷售額將達到 3.5 億美元，而日本和印度的銷售額預計將分別達到 1.9 億美元和 1.2 億美元。

拉丁美洲、中東和非洲

由於診斷率的提高和獲得最新失眠治療方案的便利，預計這些地區將實現溫和成長。公眾意識的提高和醫療基礎設施的改善將繼續推動市場擴張。

近期產業發展包括「QUVIVIQ（達利德沙烏地）」的持續全球擴張、策略授權合作以及在重點市場推出先進的Orexin受體拮抗劑療法。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家/地區失眠盛行率
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）
  • 主要國家和地區的監管狀況

第5章：2021-2034年全球失眠治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 雙重Orexin受體拮抗劑（DORA）
    • Z類藥物/非苯二氮平類催眠藥
    • 苯二氮平類催眠藥
    • 褪黑素路徑促效劑
    • 其他
  • 市場分析、洞察與預測：按疾病適應症分類
    • 原發性慢性失眠
    • 與併發精神疾病相關的失眠
    • 伴隨神經性/疼痛相關性失眠
    • 短期/適應期失眠
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 成人
    • 兒童
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 非專利的
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美失眠治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲失眠治療市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區失眠治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲失眠治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東與非洲失眠治療市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Eisai Co., Ltd.
    • Idorsia Ltd
    • Merck & Co., Inc.
    • Takeda Pharmaceutical Company Limited
    • Sanofi
    • Pfizer Inc.
    • Currax Pharmaceuticals LLC
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Limited
Product Code: FBI116040

Growth Factors of insomnia drugs Market

The global insomnia drugs market was valued at USD 4.50 billion in 2025 and is projected to grow from USD 4.86 billion in 2026 to USD 8.90 billion by 2034, registering a CAGR of 7.86% during the forecast period. North America dominated the market with a 44.88% share in 2025, driven by a high prevalence of sleep disorders, strong healthcare infrastructure, and rapid adoption of innovative insomnia therapies.

Insomnia has become one of the most common sleep disorders worldwide, affecting millions of individuals across different age groups. Rising stress levels, anxiety, depression, changing lifestyles, excessive screen exposure, and irregular work schedules have significantly increased the number of patients seeking medical intervention for sleep-related disorders. The growing burden of chronic insomnia is encouraging pharmaceutical companies to develop safer and more effective treatment options that improve both nighttime sleep quality and daytime functioning.

The market is witnessing a notable shift toward next-generation therapies, particularly Dual Orexin Receptor Antagonists (DORAs), which offer improved efficacy and reduced next-day sedation compared to traditional hypnotic drugs. Continuous research and development activities by major pharmaceutical companies are expected to drive future market growth.

Market Trends

Rising Preference for Safer and Better-Tolerated Insomnia Therapies

One of the most significant trends in the insomnia drugs market is the growing demand for therapies that provide effective sleep benefits with fewer side effects. Patients and healthcare providers are increasingly cautious about conventional sleep medications due to concerns regarding dependency, cognitive impairment, and residual daytime drowsiness.

As a result, newer therapies such as orexin receptor antagonists are gaining popularity. These drugs are designed to promote natural sleep patterns while minimizing next-morning impairment. The increasing focus on improving both sleep quality and daytime performance is reshaping prescribing patterns globally.

Market Drivers

Increasing Prevalence of Insomnia and Sleep Disorders

The primary driver of market growth is the rapidly increasing prevalence of insomnia worldwide. Growing mental health concerns, aging populations, work-related stress, and chronic health conditions have significantly increased the number of patients experiencing sleep disturbances.

According to recent global studies, more than 850 million adults worldwide suffer from insomnia, creating substantial demand for pharmaceutical treatment options. As awareness regarding the importance of sleep health continues to rise, diagnosis rates and treatment-seeking behavior are expected to increase further, supporting long-term market expansion.

Market Restraints

Safety Concerns Associated with Long-Term Drug Use

Despite growing demand, concerns regarding long-term safety remain a major challenge for the market. Several insomnia medications are associated with dependency risks, falls, residual sedation, and cognitive impairment, particularly among elderly patients.

Healthcare providers often recommend short-term use of certain sleep medications, limiting long-term prescription growth. These concerns continue to influence prescribing decisions and slow broader adoption of some drug classes.

Market Opportunities

Growing Awareness of Sleep Health

Increasing awareness about the impact of sleep on physical and mental well-being presents significant opportunities for market expansion. Patients are becoming more proactive in seeking treatment for chronic sleep disorders, while healthcare providers are emphasizing sleep management as part of overall wellness programs.

Pharmaceutical companies are also expanding into emerging markets through partnerships, licensing agreements, and commercialization initiatives to improve access to innovative insomnia therapies.

Market Challenges

Generic Competition and Patent Expirations

One of the key challenges facing the insomnia drugs market is the growing availability of generic alternatives. As patents expire, lower-cost generic versions gain market share, reducing revenue opportunities for branded manufacturers.

Price pressure from generic products is intensifying competition and forcing pharmaceutical companies to focus on innovation and product differentiation to maintain profitability.

Segment Analysis

By Drug Class

The Z-drugs/non-benzodiazepine hypnotics segment dominated the market in 2025 due to widespread physician familiarity and long-standing use in treating sleep onset and sleep maintenance difficulties. Drugs such as zolpidem and zopiclone continue to generate significant prescription volumes globally.

The Dual Orexin Receptor Antagonists (DORAs) segment is expected to be the fastest-growing category, registering a CAGR of 18.28% during the forecast period. Increasing acceptance of innovative therapies such as daridorexant and lemborexant is driving growth.

By Disease Indication

The primary chronic insomnia disorder segment held the largest market share in 2025. Chronic insomnia patients often require ongoing treatment, generating recurring demand for pharmaceutical therapies.

By Age Group

The adult segment dominated the market in 2025. Adults are more likely to experience insomnia due to stress, anxiety, work schedules, and age-related sleep disturbances. Most approved insomnia therapies are also specifically indicated for adult patients.

By Type

The generic drugs segment accounted for the largest share due to lower costs and broad accessibility. Generic versions of established insomnia medications remain widely prescribed in both developed and developing markets.

However, the branded segment is expected to grow at a CAGR of 10.05% through 2034, supported by the launch of innovative therapies.

By Route of Administration

The oral segment dominated the market because tablets and capsules offer convenience, ease of administration, and better patient compliance. Most leading insomnia drugs are available in oral formulations.

By Distribution Channel

The drug stores and retail pharmacies segment accounted for the largest market share in 2025. Since insomnia is primarily managed in outpatient settings, retail pharmacies remain the preferred dispensing channel for recurring prescriptions.

Regional Analysis

North America

North America led the global market with a valuation of USD 2.02 billion in 2025. Strong awareness regarding sleep disorders, favorable reimbursement policies, and rapid adoption of innovative insomnia therapies continue to support growth.

The U.S. insomnia drugs market is estimated at USD 2.01 billion in 2026, representing approximately 41.29% of global revenue.

Europe

Europe is projected to reach USD 1.31 billion in 2026, growing at a CAGR of 7.79%. Increased physician confidence in DORA therapies and broader reimbursement support are driving market expansion.

Germany and the U.K. remain among the largest regional markets.

Asia Pacific

Asia Pacific is expected to reach USD 1.01 billion in 2026, driven by increasing awareness of sleep health, rising healthcare spending, and growing adoption of branded insomnia medications.

China is projected to generate USD 0.35 billion in revenue in 2026, while Japan and India are estimated to reach USD 0.19 billion and USD 0.12 billion, respectively.

Latin America and Middle East & Africa

These regions are expected to experience moderate growth due to increasing diagnosis rates and improving access to modern insomnia therapies. Growing awareness and healthcare infrastructure development will continue to support market expansion.

Competitive Landscape

The insomnia drugs market is highly consolidated, with major pharmaceutical companies focusing on product innovation, strategic collaborations, licensing agreements, and geographical expansion.

Key companies operating in the market include:

  • Eisai Co., Ltd.
  • Idorsia Ltd
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Pfizer Inc.
  • Currax Pharmaceuticals LLC
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Lupin Limited

Recent industry developments include the continued global expansion of QUVIVIQ (daridorexant), strategic licensing partnerships, and the launch of advanced orexin receptor antagonist therapies across major markets.

Conclusion

The global insomnia drugs market is poised for sustained growth, expanding from USD 4.50 billion in 2025 to USD 8.90 billion by 2034. Rising prevalence of chronic insomnia, growing awareness of sleep health, increasing treatment-seeking behavior, and continuous innovation in orexin receptor antagonist therapies are expected to drive market expansion. Although challenges such as safety concerns and generic competition remain, the development of safer, more effective, and better-tolerated insomnia medications will continue to create substantial growth opportunities. As healthcare systems place greater emphasis on sleep health and overall well-being, the insomnia drugs market is expected to remain a vital segment of the global pharmaceutical industry throughout the forecast period.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * Dual Orexin Receptor Antagonists (DORAs)

  • Z-drugs/Non-Benzodiazepine Hypnotics
  • Benzodiazepine Hypnotics
  • Melatonin Pathway Agents
  • Others

By Disease Indication * Primary Chronic Insomnia Disorder

  • Comorbid Psychiatric Insomnia
  • Comorbid Neurologic/Pain-Related Insomnia
  • Short-Term/Adjustment Insomnia
  • Others

By Age Group * Adults

  • Pediatrics

By Type * Branded

  • Generic

By Route of Administration * Oral

  • Others

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Insomnia, By Key Countries /Regions, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Dual Orexin Receptor Antagonists (DORAs)
    • 5.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
    • 5.1.3. Benzodiazepine Hypnotics
    • 5.1.4. Melatonin Pathway Agents
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Primary Chronic Insomnia Disorder
    • 5.2.2. Comorbid Psychiatric Insomnia
    • 5.2.3. Comorbid Neurologic/Pain-Related Insomnia
    • 5.2.4. Short-Term/Adjustment Insomnia
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Adults
    • 5.3.2. Pediatrics
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Generic
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Others
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Drug Stores & Retail Pharmacies
    • 5.6.3. Online Pharmacies
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Dual Orexin Receptor Antagonists (DORAs)
    • 6.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
    • 6.1.3. Benzodiazepine Hypnotics
    • 6.1.4. Melatonin Pathway Agents
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Primary Chronic Insomnia Disorder
    • 6.2.2. Comorbid Psychiatric Insomnia
    • 6.2.3. Comorbid Neurologic/Pain-Related Insomnia
    • 6.2.4. Short-Term/Adjustment Insomnia
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Adults
    • 6.3.2. Pediatrics
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Generic
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Others
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Drug Stores & Retail Pharmacies
    • 6.6.3. Online Pharmacies
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Dual Orexin Receptor Antagonists (DORAs)
    • 7.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
    • 7.1.3. Benzodiazepine Hypnotics
    • 7.1.4. Melatonin Pathway Agents
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Primary Chronic Insomnia Disorder
    • 7.2.2. Comorbid Psychiatric Insomnia
    • 7.2.3. Comorbid Neurologic/Pain-Related Insomnia
    • 7.2.4. Short-Term/Adjustment Insomnia
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Adults
    • 7.3.2. Pediatrics
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Generic
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Oral
    • 7.5.2. Others
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Drug Stores & Retail Pharmacies
    • 7.6.3. Online Pharmacies
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Dual Orexin Receptor Antagonists (DORAs)
    • 8.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
    • 8.1.3. Benzodiazepine Hypnotics
    • 8.1.4. Melatonin Pathway Agents
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Primary Chronic Insomnia Disorder
    • 8.2.2. Comorbid Psychiatric Insomnia
    • 8.2.3. Comorbid Neurologic/Pain-Related Insomnia
    • 8.2.4. Short-Term/Adjustment Insomnia
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Adults
    • 8.3.2. Pediatrics
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Generic
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Oral
    • 8.5.2. Others
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Drug Stores & Retail Pharmacies
    • 8.6.3. Online Pharmacies
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Dual Orexin Receptor Antagonists (DORAs)
    • 9.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
    • 9.1.3. Benzodiazepine Hypnotics
    • 9.1.4. Melatonin Pathway Agents
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Primary Chronic Insomnia Disorder
    • 9.2.2. Comorbid Psychiatric Insomnia
    • 9.2.3. Comorbid Neurologic/Pain-Related Insomnia
    • 9.2.4. Short-Term/Adjustment Insomnia
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Adults
    • 9.3.2. Pediatrics
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Generic
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Oral
    • 9.5.2. Others
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Drug Stores & Retail Pharmacies
    • 9.6.3. Online Pharmacies
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Dual Orexin Receptor Antagonists (DORAs)
    • 10.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
    • 10.1.3. Benzodiazepine Hypnotics
    • 10.1.4. Melatonin Pathway Agents
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Primary Chronic Insomnia Disorder
    • 10.2.2. Comorbid Psychiatric Insomnia
    • 10.2.3. Comorbid Neurologic/Pain-Related Insomnia
    • 10.2.4. Short-Term/Adjustment Insomnia
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Adults
    • 10.3.2. Pediatrics
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Generic
  • 10.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.5.1. Oral
    • 10.5.2. Others
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Drug Stores & Retail Pharmacies
    • 10.6.3. Online Pharmacies
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Eisai Co., Ltd.
    • 11.2.2. Idorsia Ltd
    • 11.2.3. Merck & Co., Inc.
    • 11.2.4. Takeda Pharmaceutical Company Limited
    • 11.2.5. Sanofi
    • 11.2.6. Pfizer Inc.
    • 11.2.7. Currax Pharmaceuticals LLC
    • 11.2.8. Viatris Inc.
    • 11.2.9. Teva Pharmaceutical Industries Ltd.
    • 11.2.10. Lupin Limited

List of Tables

  • Figure 1: Global Insomnia Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Insomnia Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Insomnia Drugs Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Insomnia Drugs Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Insomnia Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 6: Global Insomnia Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Insomnia Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 8: Global Insomnia Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Insomnia Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 10: North America Insomnia Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 11: North America Insomnia Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Insomnia Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Insomnia Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 14: North America Insomnia Drugs Market Value Share (%), by Age Group 2025
  • Figure 15: North America Insomnia Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 16: North America Insomnia Drugs Market Value Share (%), by Type, 2025
  • Figure 17: North America Insomnia Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 18: North America Insomnia Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 19: North America Insomnia Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Insomnia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Insomnia Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Insomnia Drugs Market Value Share (%), by Country, 2025
  • Figure 23: Europe Insomnia Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 24: Europe Insomnia Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 25: Europe Insomnia Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 26: Europe Insomnia Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 27: Europe Insomnia Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 28: Europe Insomnia Drugs Market Value Share (%), by Age Group 2025
  • Figure 29: Europe Insomnia Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 30: Europe Insomnia Drugs Market Value Share (%), by Type, 2025
  • Figure 31: Europe Insomnia Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Europe Insomnia Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Europe Insomnia Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Europe Insomnia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Insomnia Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Insomnia Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Insomnia Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Insomnia Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 39: Asia Pacific Insomnia Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 40: Asia Pacific Insomnia Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 41: Asia Pacific Insomnia Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 42: Asia Pacific Insomnia Drugs Market Value Share (%), by Age Group 2025
  • Figure 43: Asia Pacific Insomnia Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 44: Asia Pacific Insomnia Drugs Market Value Share (%), by Type, 2025
  • Figure 45: Asia Pacific Insomnia Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 46: Asia Pacific Insomnia Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 47: Asia Pacific Insomnia Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Insomnia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 49: Asia Pacific Insomnia Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Insomnia Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Insomnia Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 52: Latin America Insomnia Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 53: Latin America Insomnia Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 54: Latin America Insomnia Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 55: Latin America Insomnia Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 56: Latin America Insomnia Drugs Market Value Share (%), by Age Group 2025
  • Figure 57: Latin America Insomnia Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 58: Latin America Insomnia Drugs Market Value Share (%), by Type, 2025
  • Figure 59: Latin America Insomnia Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 60: Latin America Insomnia Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 61: Latin America Insomnia Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Insomnia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 63: Latin America Insomnia Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Insomnia Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Insomnia Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Insomnia Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 67: Middle East & Africa Insomnia Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 68: Middle East & Africa Insomnia Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 69: Middle East & Africa Insomnia Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 70: Middle East & Africa Insomnia Drugs Market Value Share (%), by Age Group 2025
  • Figure 71: Middle East & Africa Insomnia Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 72: Middle East & Africa Insomnia Drugs Market Value Share (%), by Type, 2025
  • Figure 73: Middle East & Africa Insomnia Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 74: Middle East & Africa Insomnia Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 75: Middle East & Africa Insomnia Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Insomnia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 77: Middle East & Africa Insomnia Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Insomnia Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Insomnia Drugs Market Share (%), by Company, 2025